Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
What caused my MGUS, SMM, MM is the first question many of us ask ourselves upon diagnosis. It might be cold comfort but pesticide use increases the risk of Multiple Myeloma (MM) too. While I didn’t work around pesticides before my diagnosis of multiple myeloma, I did work in a commercial printing plant and was exposed to chemicals. While I can’t say for certain that your MGUS cause was pesticide use, it’s important for you to know that pesticide exposure can increase the risk of an MGUS diagnosis. Further, this diagnosis is a blood disorder or pre-myeloma, not cancer.
Hi. My name is David Emerson. I am both a long-term Multiple Myeloma survivor and MM cancer coach. MMers wonder about the origins of their myeloma. So I thought MGUS patients might want to know as well.
MGUS at a glance-
While it may not help you to learn that working on the farm all those years increased your risk for MGUS it may help you to learn that there are evidence-based, non-toxic therapies that can decrease the risk of your MGUS becoming a full-blown MM diagnosis. You can do more than just “watch and wait.”
To learn more about these evidence-based, non-toxic therapies, please watch the short video below:
Consider MGUS Therapies such as:
“Pesticides are associated with excess risk of multiple myeloma, albeit inconclusively. We included 678 men (30-94 years) from a well-characterized prospective cohort of restricted-use pesticide applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS).
Serum samples from all subjects were analyzed by electrophoresis performed on agarose gel; samples with a discrete or localized band were subjected to immunofixation. Age-adjusted prevalence estimates of MGUS were compared with MGUS prevalence in 9469 men from Minnesota.
Associations between pesticide exposures and MGUS prevalence were assessed by logistic regression models adjusted for age and education level. Among study participants older than 50 years (n = 555), 38 were found to have MGUS, yielding a prevalence of 6.8% (95% CI, 5.0%-9.3%). Compared with men from Minnesota, the age-adjusted prevalence of MGUS was 1.9-fold (95% CI, 1.3- to 2.7-fold) higher among male pesticide applicators.
Among applicators, a 5.6-fold (95% CI, 1.9- to 16.6-fold), 3.9-fold (95% CI, 1.5- to 10.0-fold), and 2.4-fold (95% CI, 1.1- to 5.3-fold) increased risk of MGUS prevalence was observed among users of the chlorinated insecticide dieldrin, the fumigant mixture carbon-tetrachloride/carbon disulfide, and the fungicide chlorothalonil, respectively. In summary, the prevalence of MGUS among pesticide applicators was twice that in a population-based sample of men from Minnesota, adding support to the hypothesis that specific pesticides are causatively linked to myelomagenesis.”